Intravenous haloperidol or chlorpromazine—which is more effective to improve agitation and communication in agitated delirium at the end of life?
Intravenous haloperidol and chlorpromazine are not statistically different for terminal agitation. These results should be validated in clinical trials.
Authors
- Yuki Watanabe (ORCID: https://orcid.org/0000-0002-4258-4329)
- Yoshinobu Matsuda (ORCID: https://orcid.org/0000-0003-1772-4518)
- Nobuhisa Nakajima (ORCID: https://orcid.org/0000-0002-5416-1227)
- Koji Amano (ORCID: https://orcid.org/0000-0002-1779-6389)
- Shingo Hagiwara
- Isseki Maeda (ORCID: https://orcid.org/0000-0002-0018-3359)
- Ryohei Tatara
- Satoshi Inoue (ORCID: https://orcid.org/0000-0003-1247-3844)
- Tatsuo Akechi (ORCID: https://orcid.org/0000-0003-1100-7518)
- Takuya Odagiri (ORCID: https://orcid.org/0000-0002-6488-5595)
- Naoki Matsuo (ORCID: https://orcid.org/0000-0001-8346-1627)
- Kazuhiro Yoshiuchi (ORCID: https://orcid.org/0000-0002-8164-4910)
- Sachiyo Morita
- Tatsuya Morita (ORCID: https://orcid.org/0000-0002-7257-7429)
- Megumi Uchida (ORCID: https://orcid.org/0000-0003-2815-8400)
- Nobuya Akizuki
- Ichiro Mori (ORCID: https://orcid.org/0000-0001-7021-7895)
- Takuya Kawahara (ORCID: https://orcid.org/0000-0002-3859-2756)
- Asao Ogawa (ORCID: https://orcid.org/0000-0003-0436-6934)
- Akihiro Tokoro (ORCID: https://orcid.org/0000-0002-0635-7647)
- Emi Takeuchi (ORCID: https://orcid.org/0000-0003-1632-6876)
- Naosuke Yokomichi (ORCID: https://orcid.org/0000-0003-0863-1184)
- Takayuki Hisanaga
- Shuji Inada
- Hiroyuki Nobata
- Hirofumi Abo
- Rika Nakahara
- Ritsuko Yabuki
- Yoshihisa Matsumoto (ORCID: https://orcid.org/0000-0003-3112-4818)
- Toru Okuyama (ORCID: https://orcid.org/0000-0003-0504-6406)
- Takeshi Hirohashi
- Akihiro Sakashita (ORCID: https://orcid.org/0000-0003-0477-8875)
- Aio Iwata
- Kengo Imai (ORCID: https://orcid.org/0009-0003-6962-1518)
- Hiroaki Watanabe (ORCID: https://orcid.org/0000-0003-2220-2247)
- Takashi Matsui (ORCID: https://orcid.org/0000-0001-9442-9649)
- Ken Shimizu (ORCID: https://orcid.org/0000-0002-8761-7534)
- Kaya Miyajima
- Akifumi Kumano
- Toshihiro Yamauchi
- Keiichi Uemura
- Satoru Iwase
- Mari Takeuchi
- Keisuke Kanehashi
Institutions
- Hamamatsu University (JP)
- Cancer Institute (WIA) (IN)
- Nagoya City University (JP)
- National Cancer Center (US)
- Seirei Mikatabara General Hospital (JP)
- Tonan Hospital (JP)
- Japan Association for Development of Community Medicine (JP)
- University of Tokyo Hospital (JP)
- Nagoya City University Hospital (JP)
- Saitama Medical University Hospital (JP)
- Himeji Medical Center (JP)
- National Cancer Center Hospital East (JP)
- Japanese Foundation For Cancer Research (JP)
- The University of Tokyo (JP)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-09-27
- DOI
- https://doi.org/10.1093/oncolo/oyaf324
- Primary Topic
- Intensive Care Unit Cognitive Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- AstraZeneca
- EA Pharma Co., Ltd.
- Kowa Company
- Mylan
- Nipro
- Daiichi-Sankyo
- Eisai
- Meiji Seika Pharma
- University of Tokyo
- Astellas Pharma
- Shionogi
- Otsuka Pharmaceutical
- Nagoya City University
- H. Lundbeck A/S
- Chugai Pharmaceutical
- Japan Society for the Promotion of Science
- Daiichi Sankyo Europe